Mohammadi Faezeh, Hashemi Seyed Jamal, Zoll Jan, Melchers Willem J G, Rafati Haleh, Dehghan Parvin, Rezaie Sasan, Tolooe Ali, Tamadon Yalda, van der Lee Henrich A, Verweij Paul E, Seyedmousavi Seyedmojtaba
Department of Medical Mycology and Parasitology, School of Hygiene & Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):387-92. doi: 10.1128/AAC.02326-15. Print 2016 Jan.
We employed an endpoint genotyping method to update the prevalence rate of positivity for the TR34/L98H mutation (a 34-bp tandem repeat mutation in the promoter region of the cyp51A gene in combination with a substitution at codon L98) and the TR46/Y121F/T289A mutation (a 46-bp tandem repeat mutation in the promoter region of the cyp51A gene in combination with substitutions at codons Y121 and T289) among clinical Aspergillus fumigatus isolates obtained from different regions of Iran over a recent 5-year period (2010 to 2014). The antifungal activities of itraconazole, voriconazole, and posaconazole against 172 clinical A. fumigatus isolates were investigated using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution method. For the isolates with an azole resistance phenotype, the cyp51A gene and its promoter were amplified and sequenced. In addition, using a LightCycler 480 real-time PCR system, a novel endpoint genotyping analysis method targeting single-nucleotide polymorphisms was evaluated to detect the L98H and Y121F mutations in the cyp51A gene of all isolates. Of the 172 A. fumigatus isolates tested, the MIC values of itraconazole (≥16 mg/liter) and voriconazole (>4 mg/liter) were high for 6 (3.5%). Quantitative analysis of single-nucleotide polymorphisms showed the TR34/L98H mutation in the cyp51A genes of six isolates. No isolates harboring the TR46/Y121F/T289A mutation were detected. DNA sequencing of the cyp51A gene confirmed the results of the novel endpoint genotyping method. By microsatellite typing, all of the azole-resistant isolates had genotypes different from those previously recovered from Iran and from the Dutch TR34/L98H controls. In conclusion, there was not a significant increase in the prevalence of azole-resistant A. fumigatus isolates harboring the TR34/L98H resistance mechanism among isolates recovered over a recent 5-year period (2010 to 2014) in Iran. A quantitative assay detecting a single-nucleotide polymorphism in the cyp51A gene of A. fumigatus is a reliable tool for the rapid screening and monitoring of TR34/L98H- and TR46/Y121F/T289A-positive isolates and can easily be incorporated into clinical mycology algorithms.
我们采用终点基因分型方法,以更新近期5年期间(2010年至2014年)从伊朗不同地区获得的临床烟曲霉分离株中TR34/L98H突变(cyp51A基因启动子区域的34bp串联重复突变,同时伴有密码子L98处的替换)和TR46/Y121F/T289A突变(cyp51A基因启动子区域的46bp串联重复突变,同时伴有密码子Y121和T289处的替换)的阳性率。采用欧洲抗菌药物敏感性试验委员会(EUCAST)肉汤微量稀释法,研究了伊曲康唑、伏立康唑和泊沙康唑对172株临床烟曲霉分离株的抗真菌活性。对于具有唑类耐药表型的分离株,扩增并测序cyp51A基因及其启动子。此外,使用LightCycler 480实时PCR系统,评估了一种针对单核苷酸多态性的新型终点基因分型分析方法,以检测所有分离株cyp51A基因中的L98H和Y121F突变。在172株受试烟曲霉分离株中,6株(3.5%)伊曲康唑(≥16mg/L)和伏立康唑(>4mg/L)的最低抑菌浓度值较高。单核苷酸多态性定量分析显示,6株分离株的cyp51A基因存在TR34/L98H突变。未检测到携带TR46/Y121F/T289A突变的分离株。cyp51A基因的DNA测序证实了新型终点基因分型方法的结果。通过微卫星分型,所有唑类耐药分离株的基因型均与先前从伊朗和荷兰TR34/L98H对照中获得的基因型不同。总之,在伊朗近期5年期间(2010年至2014年)分离的烟曲霉分离株中,携带TR34/L98H耐药机制的唑类耐药分离株的流行率没有显著增加。一种检测烟曲霉cyp51A基因单核苷酸多态性的定量测定方法,是快速筛选和监测TR34/L98H和TR46/Y121F/T289A阳性分离株的可靠工具,并且可以很容易地纳入临床真菌学算法中。